The stock's next major catalyst is the Phase 3 denifanstat acne trial initiation in H2 2026. With $257.6M cash funding operations through 2028, there is no near-term financing risk. Monitor for enrollment updates and any data readouts from the ongoing TVB-3567 Phase 1 trial, which could provide additional pipeline optionality.
Price Chart
Executive Summary
Sagimet Biosciences reported Q2 2026 net loss of $14.0 million ($0.26 per share), wider than the $10.4 million loss in Q2 2025, reflecting increased R&D spending as the company advances denifanstat toward a Phase 3 acne trial. The company ended the quarter with $257.6 million in cash, following a $175 million equity financing in April, providing runway through 2028. The key catalyst is the upcoming Phase 3 initiation for denifanstat in moderate-to-severe acne in H2 2026, which represents a potential first-in-class oral treatment for a large underserved market.
Key Financial Metrics
Key Facts
- Net loss for Q2 2026 was $14.0 million, vs $10.4 million in Q2 2025
- Cash, cash equivalents and marketable securities of $257.6 million as of June 30, 2026
- Completed $175.0 million equity financing in April 2026
- Phase 3 trial of denifanstat in moderate-to-severe acne on track for H2 2026 initiation
- Phase 1 trial of TVB-3567 ongoing; Phase 2 planned before end of 2026
- R&D expense $11.5 million in Q2 2026, up from $7.2 million in Q2 2025
- Weighted-average shares outstanding increased to 53.1M from 32.2M year-over-year due to equity financing
Financial Impact
Net loss of $14.0 million in Q2 2026, cash burn rate ~$5M/month; $257.6M cash provides runway through 2028
Risk Factors
- Clinical trial failure or delay for denifanstat Phase 3 acne trial
- Dilution from April 2026 equity financing increased share count by 65%
- No revenue; pre-commercialization stage with ongoing operating losses
- Competition from existing acne treatments and other pipeline candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342598 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $9.95 $9.58 | ▼ −3.72% | ▼ −3.20% | $9.58 (−3.72%) |
Oct 7, 2026 19d ago | SC 13G | $8.92 $8.93 | ▲ +0.11% | ▼ −0.49% | $9.58 (+7.40%) |
Oct 1, 2026 25d ago | Press Release | $9.14 $9.03 | ▲ +1.20% | ▲ +1.88% | $9.58 (−4.81%) |
Sep 30, 2026 26d ago | Press Release | $9.88 $9.37 | ▲ +5.16% | ▲ +5.34% | $9.58 (+3.04%) |
Sep 30, 2026 26d ago | 8-K | $9.88 $9.37 | ▼ −5.16% | ▼ −5.34% | $9.58 (−3.04%) |
Sep 22, 2026 4w ago | Institutional Cluster | $11.09 $10.42 | ▼ −6.04% | ▼ −5.32% | $9.58 (−13.62%) |
Aug 25, 2026 8w ago | Press Release | $10.29 $10.86 | ▲ +5.54% | ▲ +5.52% | $9.58 (−6.90%) |
Aug 11, 2026 10w ago | 8-K | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $9.58 (+0.63%) |
Aug 11, 2026 10w ago | Press Release | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $9.58 (+0.63%) |
Jul 22, 2026 13w ago | Insider Cluster | $7.01 $7.07 | ▲ +0.86% | ▲ +0.75% | $9.58 (+36.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers